MedTrace Logo

Liposomal Bupivacaine in Rotator Cuff Repair

NCT03738696 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-05-16

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of interscalene liposomal bupivacaine in controlling postoperative pain scores, oral morphine equivalents and sleep quality after arthroscopic rotator cuff repair surgery as compared to interscalene catheter.

Conditions

  • Rotator Cuff Injury

Interventions

DRUG

Exparel

A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain

DRUG

Ropivacaine

A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-15
Primary Completion
2022-01-01
Completion
2022-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03738696 on ClinicalTrials.gov